| 000 | 01631 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516024010.0 | ||
| 264 | 0 | _c20111024 | |
| 008 | 201110s 0 0 eng d | ||
| 022 | _a1573-2665 | ||
| 024 | 7 |
_a10.1007/s10545-011-9280-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGlamuzina, Emma | |
| 245 | 0 | 0 |
_aTreatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. _h[electronic resource] |
| 260 |
_bJournal of inherited metabolic disease _cJun 2011 |
||
| 300 |
_a749-54 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article | ||
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xmethods |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aEndpoint Determination _xmethods |
| 650 | 0 | 4 | _aEnzyme Replacement Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIduronate Sulfatase _xtherapeutic use |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMucopolysaccharidosis II _xdiagnosis |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aFettes, Emma | |
| 700 | 1 | _aBainbridge, Katie | |
| 700 | 1 | _aCrook, Victoria | |
| 700 | 1 | _aFinnegan, Niamh | |
| 700 | 1 | _aAbulhoul, Lara | |
| 700 | 1 | _aVellodi, Ashok | |
| 773 | 0 |
_tJournal of inherited metabolic disease _gvol. 34 _gno. 3 _gp. 749-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10545-011-9280-1 _zAvailable from publisher's website |
| 999 |
_c20604395 _d20604395 |
||